Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07637734 · ClinicalTrials.gov registry record · Phase 3
Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-3)
A Phase 3 study, sponsored by Verrica Pharmaceuticals.
- Not yet
- Registry status
- Phase 3
- Development phase
- 300
- Enrollment target
NCT07637734: Clinical Trial Phase 3 study, sponsored by Verrica Pharmaceuticals.
NCT07637734 is a Phase 3 study that has not yet begun recruiting, run by Verrica Pharmaceuticals. The registered enrollment target is 300 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (61% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07637734, a Phase 3 study, has not yet begun recruiting, sponsored by Verrica Pharmaceuticals.
- NOT YET RECRUITING
- Registry status
- Phase 3
- Development phase
- 300 participants
- Enrollment target
Study Summary
This is a Phase 3, double-blind, randomized, vehicle-controlled study (Study number VP-CW-302; referred to as COVE-3 \[Cantharidin and Occlusion in Verruca Epithelium\]) to evaluate the efficacy and safety of YCANTH (VP-102/TO-208) treatment in subjects with common warts.
Primary Outcome
To evaluate the efficacy of YCANTH (VP-102/TO-208) relative to Vehicle by assessing the proportion of subjects achieving complete clearance defined by complete resolution of all common warts as assessed visually by a Blinded Assessor of all treatable common warts, at the EOT Visit (Day 84).
Interventions
- COMBINATION_PRODUCT VP-102 (US) / TO-208 (Japan)
- COMBINATION_PRODUCT Vehicle (US) / Vehicle (Japan)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2026-06 |
| Est. Completion | 2027-10 |
| Phase | Phase 3 |
What is known before NCT07637734 opens enrollment
NCT07637734 is an interventional study that assigns participants to a tested intervention. The registered 300 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (61% lower).
The record links to 0 conditions, and to 2 interventions - of which VP-102 (US) / TO-208 (Japan) is the first listed.
NCT07637734 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07637734 about?
NCT07637734 is a clinical study titled "Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-3)". This is a Phase 3, double-blind, randomized, vehicle-controlled study (Study number VP-CW-302; referred to as COVE-3 \[Cantharidin and Occlusion in Verruca Epithelium\]) to evaluate the efficacy and safety of YCANTH (VP-102/TO-208) treatment in subjects with common warts.
What is the current status of trial NCT07637734?
This trial is currently not yet recruiting. It is a Phase 3 study. The enrollment target is 300 participants. The study started on 2026-06. Estimated completion is 2027-10.
What interventions are being tested in trial NCT07637734?
The interventions under investigation include: VP-102 (US) / TO-208 (Japan) (COMBINATION_PRODUCT), Vehicle (US) / Vehicle (Japan) (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT07637734?
This trial is sponsored by Verrica Pharmaceuticals, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07637734's enrollment target sits among peer trials
300 1122nd of 2000 higher than 840 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00353483 · 300 participants
Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells
- NCT00588185 · 300 participants · NA
[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer
- NCT00682032 · 300 participants · NA
The Effect of Beta-glucan in Non-Small Cell Lung Cancer
- NCT00870064 · 300 participants · NA
The Treatment of Type I Open Fractures in Pediatrics
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia